Geroscience Hypothesis

What it states

Most of the diseases that kill us in old age — cardiovascular disease, cancer, type-2 diabetes, neurodegeneration, sarcopenia, frailty — share upstream biology (the hallmarks of aging). Therefore, an intervention that targets that shared upstream biology should delay the onset of many diseases at once, not just one.

This is the geroscience hypothesis.

Why it matters

• Resource allocation: a single geroscience drug might do more for population health than a single disease-specific drug, because it influences multiple diseases.
• Regulatory framework: FDA has historically approved drugs for specific diseases. The TAME trial is an attempt to establish a regulatory pathway for “treating aging” using a multi-disease composite endpoint.
• Individual decision-making: if you take a drug for one indication but it also slows other age-related biology, the net benefit is larger than the labelled indication suggests.

Evidence base

• Mouse interventions that act on the hallmarks (rapamycin, senolytics, caloric restriction) typically delay multiple age-related diseases in parallel.
• Some human drug classes (SGLT2 inhibitors, GLP-1 agonists) appear to deliver multi-system benefits beyond their original indications — consistent with geroscience-style biology.

Open question

Whether any single intervention can simultaneously delay all major age-related diseases in humans is the empirical question the field is trying to answer.

Related entries

Hallmarks of aging, TAME trial, Healthspan vs lifespan.